{
  "docId": "019de077-60e9-755b-a2a9-f474a1c234cc",
  "docSlug": "c7a8fd91214a0cf2ae7cadcb747376a3",
  "documentTitle": "MindMed | Investor Presentation Deck | 42 slides",
  "authorId": "mindmed",
  "authorName": "MindMed",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 17,
  "pageCount": 42,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "traction",
  "function": "show_traction",
  "density": "balanced",
  "nDataPoints": 3,
  "notes": "The slide uses a list-based framework to map clinical outcomes to target product profile attributes.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-60e9-755b-a2a9-f474a1c234cc/17",
  "deckHref": "/decks/019de077-60e9-755b-a2a9-f474a1c234cc",
  "deckJsonHref": "/decks/019de077-60e9-755b-a2a9-f474a1c234cc.json",
  "deckAnchorHref": "/decks/019de077-60e9-755b-a2a9-f474a1c234cc#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.9,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "list",
      "text": "Fast Acting: 1.8-point reduction in CGI-S within 24 hours (p<0.0001); Durable Activity: 21.9-point improvement in HAM-A at Week 12 (p=0.003); Response / Remission: 48% of participants in remission at Week 12; Limited Side Effect Burden; Scalability",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3c342bed-097d-4064-8cc9-3f84685c9a05",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.17,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "1. Source: Study MMED008 internal study documents and calculations. 100 µg dose group. 2. Represents all analyzed secondary endpoints in week 12 topline analysis, including HAM-A, CGI-S and MADRS. 3. p-values not calculated for remission rates between groups. CGI-S: Clinical Global Impressions – Severity; HAM-A: Hamilton Anxiety Scale.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "99dbcb96-ec80-4314-a760-d6782d3aaa04",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Phase 2 Results in GAD Delivered on Target Product Profile after Single Dose and Support Phase 3 Advancement",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3f75667a-b88d-4a8b-bbd5-debad96ae038",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "e56ad00f-3135-4b22-9455-0785d218a428",
      "evidence": "list/bullet: Fast Acting: 1.8-point reduction in CGI-S within 24 hours (p<0.0001); Durable Activity: 21.9-point improvement in HAM-A at Week 12 (p=0.003); Response / Remission: 48% of participants in remission at Week 12",
      "confidence": 0.8
    }
  ],
  "frameworks": [
    {
      "name": "list-presentation",
      "slug": null,
      "matchId": "cb7bb58a-1e9f-4d38-a09f-f166eb59786c",
      "evidence": "The slide uses a structured list to present key clinical findings.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 18,
      "from": 15,
      "beatId": "7f79eae5-2e46-4d31-b209-13e74588623a",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Size",
      "beatSlug": "sequoia-pitch-market-size",
      "evidence": "Slides 15-18 discuss phase 2 results and market potential",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 16,
      "name": "Pattern Hunter",
      "slug": "02-pattern-hunter",
      "bestFor": "Time-pressed audiences, building consensus, when data is strong",
      "matchId": "0fbcc614-45f6-482e-a9be-178cb36beb58",
      "evidence": "Slides 16-20 discuss phase 2 results and study designs",
      "position": 1,
      "objective": "Show the pattern of effectiveness in treating GAD",
      "structure": "Evidence A -> Evidence B -> Evidence C -> Pattern/Conclusion",
      "confidence": 0.6,
      "description": "Group multiple pieces of evidence that together point to a pattern or conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}